Fourteen transactions. Ten sectors. Just over $2.85 billion announced.
The headline number is not the interesting part. The interesting part is the distance between the two ends of the week. On one side, a $926MM syndicated term loan B for an AI compute platform, arranged by Morgan Stanley with MUFG, Citizens, Crédit Agricole and Wells Fargo alongside. On the other, three separate $1MM factoring lines to a staffing company, a hospital services provider and an infrastructure startup.
Different lenders, different underwriting, different documentation. Identical operational requirement underneath: know what the collateral is, know what it is worth today, and know it before the borrower does.
Here is what stood out, and what it means for managers and lenders allocating to this market.
Lambda: $926MM senior secured term loan B
Morgan Stanley Senior Funding acted as left lead arranger and joint bookrunner. MUFG joined as joint bookrunner, with Citizens Bank, Crédit Agricole and Wells Fargo as documentation agents.
Why it matters:
This is a term loan B, not a bilateral facility or a private credit club deal. That distinction carries weight. A TLB means the transaction is structured to be syndicated and traded, which means an institutional loan desk has satisfied itself that AI compute revenue and the hardware behind it can be priced by a market rather than negotiated by a single relationship lender.
Twelve months ago, most GPU and data centre financing sat in venture debt, vendor finance or bespoke private credit structures. A near-billion-dollar TLB moves the category several steps closer to mainstream leveraged finance. For asset managers, that is a signal about where the next generation of asset-based opportunity is forming.
Key risks:
Residual value is the central question. GPUs depreciate on a technology curve, not a straight line, and a refresh cycle can reprice a collateral pool faster than an annual appraisal can capture it.
Beyond that: customer concentration in contracted compute revenue, dependency on power availability and site leases that sit outside the borrower’s balance sheet, and refinancing risk at maturity in a market that has not yet been tested through a full cycle.
Opportunities:
Lenders who build genuine competence in compute collateral will price it better than generalists for the next several years. That competence is largely a data problem: tracking hardware vintage, utilisation, contract tenor and counterparty quality at the asset level rather than the borrower level.
There is also an adjacency worth watching. Where a TLB market forms, a warehouse and forward-flow market usually follows.
The Ensign Group: $800MM revolving credit facility upsize
Truist Bank acted as administrative agent, joined by Citibank, The Huntington National Bank, U.S. Bank, Wells Fargo, Bank of America, BMO Bank, PNC Bank and Synovus Bank.
Why it matters:
Nine banks on a single healthcare revolver is a liquidity statement. Skilled nursing and senior care have spent several years being described as difficult to underwrite, and yet a scaled operator with owned real estate and predictable government and commercial receivables still assembled a full club at $800MM on amendment terms.
The lesson is not that healthcare risk has disappeared. It is that scale, transparency and operating history still clear the bank market, even in sectors that specialist lenders have been quietly dominating.
Key risks:
Reimbursement policy remains the dominant variable, and it is set outside the borrower’s control. Occupancy and labour cost pressure continue to compress operating margin. Facility-level regulatory action can impair individual assets in ways that portfolio-level covenants do not always capture. And an upsized revolver by definition consumes covenant headroom.
Opportunities:
For private credit, the read-across is in the middle market. Where the bank club serves operators of this size, sub-scale operators still need bridge, acquisition and working capital capital, and the specialist lenders active there have been compounding steadily.
For managers, healthcare ABF remains one of the more durable specialty categories in the US, precisely because it is unglamorous and data-intensive.
Core Scientific: $600MM revolver and letter of credit facility
Morgan Stanley Senior Funding acted as left lead arranger and joint bookrunner. JPMorgan Chase Bank took administrative agent and collateral agent roles alongside joint lead arranger duties, with Goldman Sachs and TD Securities as joint lead arrangers and bookrunners. The structure splits into a $100MM revolver and a $500MM letter of credit facility.
Why it matters:
The letter of credit tranche is five times the size of the revolver. That ratio is the story.
Data centre operators need to post credit support against power purchase agreements, grid interconnection commitments, equipment orders and site obligations long before they draw operating cash. Financing the pivot from crypto mining to AI hosting is therefore as much about providing collateral for contractual obligations as it is about funding capital expenditure.
This structure is a useful template for anyone underwriting energy-intensive infrastructure transitions.
Key risks:
Contingent exposure behaves differently from drawn debt. It can convert quickly and correlate badly, typically at the point when the borrower is already under pressure.
Add power price and contract exposure, capex timing against milestone commitments, site and grid concentration, and residual revenue volatility from the legacy business during the transition.
Opportunities:
Letter of credit provision is a fee-generating, capital-efficient product that many non-bank lenders have not yet built for. As infrastructure transitions multiply, so does demand for credit support facilities.
The monitoring requirement is the barrier to entry, and also the moat. Contingent exposure has to be tracked continuously, by counterparty and by trigger, or it is not really being managed.
Bond Street REIT: $300MM revolving credit facility upsize
JPMorgan Chase Bank led as lead lender, with BMO Capital Markets and KeyBanc Capital Markets as joint lead arrangers, Banco Santander participating and SouthState Bank as lender.
Why it matters:
Real estate revolvers are being upsized again, but selectively. Bank appetite has returned for borrowers where the unencumbered asset pool is transparent, the sponsor is known and the borrowing base can be evidenced rather than asserted.
That selectivity is the point. This is not a broad reopening. It is a reopening for borrowers with clean data.
Key risks:
Cap rate movement combined with appraisal lag can leave a borrowing base overstated for months. Tenant credit and lease rollover concentrate risk in ways that portfolio averages disguise. Floating rate exposure on drawn balances remains live.
Opportunities:
For managers, the gap between borrowers who can evidence a borrowing base in near real time and those who cannot is becoming a pricing gap. Lenders reward reporting quality, and increasingly they price it.
Perma-Pipe International Holdings: $139MM
J.P. Morgan Bank provided a structure comprising a $75MM revolver, a $14MM term loan and $50MM of incremental capacity.
Worth noting for the shape rather than the size. Half the facility is uncommitted incremental capacity, which gives an industrial borrower room to fund growth or acquisitions without returning to the market. Accordion and incremental structures shift the diligence burden forward, because the lender is underwriting a future borrower profile as much as the current one.
Risk: Industrial cyclicality, project concentration and working capital swings tied to contract timing.
Opportunity: Incremental capacity is a relationship-retention tool, and lenders who can model the borrower’s forward profile accurately will win the follow-on.
Lender finance: $50MM across three facilities
Pier Asset Management provided $15MM to an undisclosed small business lender and $10MM to an undisclosed patient finance platform. Pinnacle Financial Partners extended a $25MM line of credit to Loeb Term Solutions.
Why it matters:
None of these deals is large. Together they are among the most consequential of the week, because every dollar lent to a specialty lender funds a multiple of downstream origination.
Lender finance is the quiet transmission mechanism of private credit. When it is open, specialty origination expands across dozens of sectors simultaneously. Three facilities in a single week, none above $25MM, is a healthier signal about market breadth than any single large transaction.
Key risks:
The lender is underwriting a portfolio it does not originate. Advance rate discipline, eligibility criteria and the quality of the borrower’s own servicing and reporting are what stand between the facility and the underlying credit. Correlation is the hidden exposure, because a downturn hits the specialty lender’s book and its own funding at the same moment.
Opportunities:
Lender finance offers diversified exposure to specialty credit without building origination capability. The constraint is operational. It requires the ability to ingest and interrogate the borrower’s loan tape continuously rather than accepting a monthly summary at face value.
The specialty tail: seven lenders, seven sectors
Mountain Ridge Capital provided $15MM to a brick and mortar retailer. eCapital extended an $11MM healthcare receivables facility to a specialty pharmacy provider. Prestige Capital Corp. put a $3MM invoice factoring facility behind a bed frame manufacturer. Republic Business Credit, Versant Funding and TowerCap each provided $1MM lines to an infrastructure startup, a hospital service provider and a staffing company respectively.
Why it matters:
This is the part of the market that does not make headlines and does not stop. Seven lenders, seven sectors, one week. Retail, pharmacy, manufacturing, infrastructure, healthcare services and staffing, all financed against receivables and inventory rather than earnings multiples.
Aggregate this activity across a year and it is a meaningful asset class. Aggregate it across a manager’s portfolio and it is a data management problem.
Key risks:
Dilution and credit quality in the receivables pool. Customer concentration at the obligor level. Verification risk in factoring, where fraud is rare but expensive. Seasonality and obsolescence in retail inventory. In healthcare receivables specifically, payer mix and reimbursement timing drive collections more than borrower performance does.
Opportunities:
Spreads in the specialty tail have held up better than in the syndicated market, and the collateral is short-dated and self-liquidating. For managers building diversified ABF exposure, this is where duration is short, granularity is high and pricing power still sits with the lender that can monitor properly.
Takeaways
- Bank syndicates are back at the top of the market, and they are clubbing up. Nine lenders on Ensign, five on Lambda, four on Core Scientific. Banks are not competing on price everywhere. They are concentrating balance sheet on borrowers that fit, and syndicating the rest.
- Compute is being collateralised. A $926MM TLB for AI infrastructure changes what counts as financeable. Residual value, contract quality and power access are becoming standard diligence lines, and most lenders do not yet have the data models to assess them.
- Letters of credit are doing the work of debt. Core Scientific’s $500MM L/C tranche dwarfs its revolver. Contingent exposure is growing faster than drawn balances across infrastructure credit, and it demands the same monitoring discipline.
- Lender finance is compounding under the radar. Three facilities, none above $25MM, all of it origination capacity for the specialty market.
- Data quality is now a pricing input. Across every deal this week, from the $926MM syndication to the $1MM factoring line, the borrowers who cleared fastest were those able to evidence collateral, eligibility and performance rather than assert it.
How Cardo AI helps Asset Managers and Lenders
The distance between a $926MM term loan B and a $1MM factoring line is enormous in credit terms. Operationally, it is almost nothing. Both require someone to collect loan and collateral data, normalise it, test it against eligibility rules, compute a borrowing base, monitor covenants and triggers, and report to investors on time and in a defensible format.
Most teams do this across spreadsheets, servicer portals and PDFs. That works until portfolio complexity outruns headcount, which is usually the moment the opportunity set gets interesting.
Cardo AI provides the infrastructure layer for private credit, asset-based finance and structured finance:
- Loan tape ingestion across any source, format or servicer, with validation at the point of entry
- Borrowing base, eligibility and waterfall computation, automated and auditable
- Concentration, covenant and trigger monitoring, continuous rather than monthly
- Portfolio analytics and stress testing at loan level, not pool averages
- Institutional-grade investor and regulatory reporting
- Multi-asset-class onboarding, from data centre platforms and equipment lessors to healthcare receivables and factoring books
The result is that origination capacity stops being limited by operational capacity.
If you are building ABF exposure, financing specialty lenders, or trying to monitor a portfolio that has outgrown its reporting stack, we should talk.
Sources
ABL Advisor deal tables (August 24–28, 2026); company press releases via Business Wire, GlobeNewswire, PR Newswire and Bloomberg; ABF Journal; and issuer investor relations pages.
If you’re scaling an asset-based or private credit book, we should talk.